Australian dermatology company Botanix Pharmaceuticals (ASX: BOT) today revealed it has received a communication from the US Food and Drug Administration (FDA) in relation to its New Drug Application (NDA) submission for sofpironium bromide (SB) gel, 15%.
The news pushed Botanix’ shares down more than 22% to A$0.14 by close of trading today.
Botanix’ lead product is in development for the treatment of primary axillary hyperhidrosis, a medical condition where excessive sweating occurs beyond what is needed to maintain normal body temperature.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze